Europe Soft Tissue Sarcoma Market By Treatment (Targeted Therapy, Chemotherapy, Anti-Angiogenesis Drug, Radiation Therapy), By Disease Type (Local Sarcoma, Regional Sarcoma, Metastatic Sarcoma), By End User (Hospitals & Clinics, Ambulatory Surgical Centers, Others), By Country, Competition, Forecast & Opportunities, 2028

Europe soft tissue sarcoma market is expected to grow at a significant rate during the forecast period, 2024-2028. Rise in the incidence and prevalence of different types of cancers coupled with the increasing research & development (R&D) activities is anticipated to bolster the growth of the market. Rising number of people suffering from soft tissue sarcoma in the region is augmenting the growth of the market. The advent of advanced therapies such as targeted and biological are also a contributing factor. There is growing focus on personalized medicine along with the huge investment for anti-cancer treatment research, which is likely to discover the new paths for Europe soft tissue sarcoma treatment market in the coming future. Furthermore, there is an increase in number of clinical trials going on in the region which is facilitating the growth of the market. Rising ease in FDA approvals as well as the patent expiry of branded drugs are some of the factors fuelling the growth of the market.

Soft tissue sarcoma is a rare type of cancer that develops in soft tissues of a human body such as fat, muscle, nerves, fibrous tissues, or deep skin tissues.

Increasing Prevalence of Different Types of Cancers

According to the cancer research UK, there are about 4,300 new soft tissue sarcoma cases in England every year, which is around 12 every day.

Increasing Research & Development (R&D) Activities

There is rise in number of research activities on drugs and other therapies which is likely to bolster the growth of the market. Researchers are focusing on second-line therapies for the patients who relapse or are refractory as there is no approved therapies for the same. Heavy funding by the government as well as private sectors for the R&D purpose are facilitating the growth of the market.

Rise in Number of Clinical Trials

For instance, in 2021, a clinical trial for the “NBTXR3 Crystalline Nanoparticles and Radiation Therapy in Treating Randomized Patients in Two Arms with Soft Tissue Sarcoma of the Extremity and Trunk Wall” was completed.

Market Segmentation

Europe soft tissue sarcoma market is segmented into

Market Players

GlaxoSmithKline PLC, Eli Lilly Italia - S.p.A., Pfizer Deutschland GmbH., Bristol-Myers Squibb SARL, F. Hoffmann-La Roche AG, Teva Pharmaceuticals Europe BV, Celgene Europe Ltd, Zimmer GmbH, RTI UK Ltd, and Integra LifeSciences Services France SASU, are some of the leading companies in the market.